Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2275 January 2026

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:	
Reg No:	First Names:	First Names:	
Name:	Surname:	Surname:	
Address:	DOB:	Address:	
	Address:		
Fax Number:		Fax Number:	
Temozolomide			
Initial application — gliomas Applications only from a relevant specialist. Approvals valid for 12 months. Prerequisites(tick box where appropriate) The patient has a glioma			
Renewal — gliomas Current approval Number (if known):			
Initial application — neuroendocrine tumours Applications only from a relevant specialist. Approvals valid for 9 months. Prerequisites(tick boxes where appropriate) Patient has been diagnosed with metastatic or unresectable well-differentiated neuroendocrine tumour* Temozolomide is to be given in combination with capecitabine and Temozolomide is to be used in 28 day treatment cycles for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m² per day and Temozolomide to be discontinued at disease progression			
Renewal — neuroendocrine tumours Current approval Number (if known):			
No evidence of disease progression and The treatment remains appropriate and the patient is benefitting from treatment			
Initial application — ewing's sarcoma Applications only from a relevant specialist. Appro Prerequisites(tick box where appropriate) The patient has relapsed/refractory Ewin			

Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 2 Form SA2275 January 2026

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:	
Reg No:	First Names:	First Names:	
Name:	Surname:	Surname:	
Address:	DOB:	Address:	
	Address:		
Fax Number:		Fax Number:	
Temozolomide - continued			
Renewal — ewing's sarcoma			
Current approval Number (if known):			
Applications only from a relevant specialist. Approvals valid for 6 months.			
Prerequisites(tick boxes where appropriate)			
No evidence of disease progression and The treatment remains appropriate and the patient is benefitting from treatment			

Note: Indication marked with a * is an unapproved indication. Temozolomide is not subsidised for the treatment of relapsed high grade glioma.

I confirm the above details are correct and that in signing this form I understand I may be audited.